-
公开(公告)号：US20180231570A1
公开(公告)日：2018-08-16
申请号：US15943104
申请日：2018-04-02
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Andrea Horsch , Birgit Klapperich , Dirk Block , Alfred Engel , Johann Karl , Rosemarie Kientsch-Engel , Ekaterina Manuilova , Christina Rabe , Sandra Rutz , Monika Soukupova , Ursula-Henrike Wienhues-Thelen , Peter Kastner , Edelgard Anna Kaiser
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N33/68 , G01N33/74 , G01N2333/47 , G01N2333/8139 , G01N2800/347 , G01N2800/50
Abstract: The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.
-
公开(公告)号：US20180196067A1
公开(公告)日：2018-07-12
申请号：US15911699
申请日：2018-03-05
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Roberto Latini , Serge Masson , Ursula-Henrike Wienhues-Thelen , Christian Zaugg
CPC classification number: G01N33/6887 , A61B5/055 , A61B8/0883 , G01N33/82 , G01N2333/4703 , G01N2333/4706 , G01N2333/4712 , G01N2333/50 , G01N2333/78 , G01N2800/32 , G01N2800/329 , G01N2800/50
Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.
-
公开(公告)号：US20170016918A1
公开(公告)日：2017-01-19
申请号：US15285685
申请日：2016-10-05
Inventor： Ursula-Henrike Wienhues-Thelen , Georg Hess , Hendrik Huedig , Herbert von der Eltz , Andrew Emili , Anthony Gramolini , Peter Liu , David MacLennan , Vincent Fong , Ruth Isserlin , Thomas Kislinger , Dirk Block
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N2333/47 , G01N2333/4727 , G01N2333/4737 , G01N2333/4745 , G01N2333/5412 , G01N2333/58 , G01N2800/325 , G01N2800/56
Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
Abstract translation: 公开了一种用于评估体外心脏衰竭的方法，包括以下步骤：在样品中测量标记物IGFBP-7的浓度，任选地在样品中测量一种或多种其他心力衰竭标志物的浓度，以及 通过比较IGFBP-7中测定的浓度和将任选的一种或多种其它标记物测定的浓度与该参考群体中确定的该标记物或这些标记物的浓度进行比较来评估心力衰竭。 还公开了在评估心力衰竭中使用IGFBP-7作为标记蛋白，包括IGFBP-7的标记组合和用于测量IGFBP-7的试剂盒。
-
公开(公告)号：US12117454B2
公开(公告)日：2024-10-15
申请号：US16868644
申请日：2020-05-07
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Hans-Peter Brunner , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Thomas Dieterle , Cheryl Mitchell , Johan Ubby , Sandra Sanders-van Wijk
CPC classification number: G01N33/6893 , G01N33/62 , G01N33/66 , G01N33/6869 , G01N33/6887 , G01N33/70 , G01N33/723 , G01N33/84 , G01N2333/4737 , G01N2333/5412 , G01N2333/58 , G01N2333/78 , G01N2333/805 , G01N2800/325 , G01N2800/347 , G01N2800/52
Abstract: Methods for identifying a patient who is eligible for an intensification of heart failure therapy are disclosed. Furthermore, methods for optimizing B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy are disclosed. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described methods.
-
15.发明申请公开(公告)号：US20210164969A1
公开(公告)日：2021-06-03
申请号：US17162140
申请日：2021-01-29
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Ursula-Henrike Wienhues-Thelen , Dirk Block , Hendrik Heudig , Sabine Vogel-Ziebolz , Christine Boehm , Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC: G01N33/543 , G01N33/68
Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.
-
Patent Agency Ranking
公开(公告)号：US10996229B2
公开(公告)日：2021-05-04
申请号：US16598361
申请日：2019-10-10
Inventor： Ursula-Henrike Wienhues-Thelen , Georg Hess , Hendrik Huedig , Herbert von der Eltz , Andrew Emili , Anthony Gramolini , Peter Liu , David MacLennan , Vincent Fong , Ruth Isserlin , Thomas Kislinger , Dirk Block
Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
-
17.发明申请公开(公告)号：US20200271670A1
公开(公告)日：2020-08-27
申请号：US16868644
申请日：2020-05-07
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Hans-Peter Brunner , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Thomas Dieterle , Cheryl Mitchell , Johan Ubby , Sandra Sanders-van Wijk
Abstract: The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for pikej3optimizing B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.
-
公开(公告)号：US20200064359A1
公开(公告)日：2020-02-27
申请号：US16598361
申请日：2019-10-10
Inventor： Ursula-Henrike Wienhues-Thelen , Georg Hess , Hendrik Huedig , Herbert von der Eltz , Andrew Emili , Anthony Gramolini , Peter Liu , David MacLennan , Vincent Fong , Ruth Isserlin , Thomas Kislinger , Dirk Block
IPC: G01N33/68
Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
-
公开(公告)号：US20190154706A1
公开(公告)日：2019-05-23
申请号：US16257770
申请日：2019-01-25
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Hans-Peter Brunner , Thomas Dieterle , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Andre Ziegler
Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
-
公开(公告)号：US20180364248A1
公开(公告)日：2018-12-20
申请号：US16110687
申请日：2018-08-23
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Martin Hund , Edelgard Anna Kaiser , Ursula-Henrike Wienhues-Thelen , Dirk Block , Johann Karl
IPC: G01N33/68
Abstract: The present disclosure relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also disclosed are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present disclosure further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Finally, the present disclosure relates to a device or kit adapted to carry out the method of the present invention.
-
-
-
-
-
-
-
-
-
Search Results
41
records
(took 0.027 seconds)
